There were 1,609 press releases posted in the last 24 hours and 449,395 in the last 365 days.

Cell Surface Markers Market Hit $ 9.72 Bn by 2032, with an 8% CAGR: Rising Incidence of Chronic Diseases Driving Growth

Reports And Data

Reports And Data

Cell surface markers market size was USD 4.86 billion in 2022 and is expected to reach USD 9.72 billion in 2032, and register a revenue CAGR of 8%

The global cell surface markers market size was USD 4.86 billion in 2022 and is expected to reach USD 9.72 billion in 2032, and register a revenue CAGR of 8% during the forecast period.”
— Reports and Data

NEW YORK, NY, UNITED STATES, May 3, 2023 / -- The Global Cell Surface Markers Market was valued at USD 4.86 billion in 2022, and is projected to reach USD 9.72 billion by 2032, with a revenue CAGR of 8% during the forecast period. Cluster of Differentiation (CD) markers, also known as cell surface markers, are molecules found on the surface of cells that can identify and separate specific cell populations. These markers play a vital role in research and diagnostics, as they help differentiate between various cell types and their functions. Cell surface markers are increasingly being used for disease diagnosis and therapy, as there is a growing demand for personalized medicine.

The rise in chronic diseases, such as cancer, autoimmune disorders, and infectious diseases, is one of the key factors driving revenue growth in the cell surface markers market. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with an estimated 9.6 million deaths in 2018. Cell surface markers are critical in the diagnosis of such diseases, as accurate and reliable diagnostic assays are needed for early identification.

Furthermore, increased funding for research initiatives in cell-based therapeutics and diagnostics is expected to drive revenue growth in the market. Cell-based therapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy, have revolutionized cancer treatment by utilizing cell surface markers to identify and target cancer cells with higher efficacy and fewer side effects compared to conventional therapies. The growing trend towards personalized medicine is also expected to fuel demand for cell surface markers, as they are crucial in creating customized treatments for individual patients.

Get Free Sample PDF (To Understand the Complete Structure of this Report [Summary + TOC]) @

Segments Covered in the Report

Cell analysis is an essential tool for understanding cellular behavior and function. It involves the study of cells, their properties, and their functions in living organisms. With the rise of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, there has been an increase in demand for cell analysis, driving the growth of the global market.

Based on product type, the market for cell analysis is segmented into antibodies, PCR arrays, flow cytometry, and others. Antibodies are widely used in cell analysis as they are highly specific and can recognize and bind to specific molecules on cell surfaces. PCR arrays are also commonly used as they allow for the analysis of multiple genes in a single reaction. Flow cytometry is another important tool in cell analysis, allowing for the analysis of individual cells based on their physical and chemical properties. Other products in the market include microscopes, high-content screening systems, and cell counters.

On the basis of application, the market is segmented into research, clinical diagnostics, and drug discovery. Research is the largest segment of the market, with a significant portion of research funding going towards cell analysis. Clinical diagnostics is also a significant segment as cell analysis is used for disease diagnosis and monitoring. With the increasing emphasis on personalized medicine, the use of cell analysis in drug discovery is also expected to grow.

In conclusion, the global cell analysis market is seeing significant growth driven by the increasing prevalence of chronic diseases, rising demand for personalized medicine, and the growing need for cell-based therapies. As the market continues to evolve, technological advancements and innovations in products are expected to drive further growth.

Access Full Report Description with Research Methodology and Table of Contents @

Strategic development:

In 2021, BD Biosciences launched a new panel of cell surface markers that consists of 30 markers for the identification of immune cells in human blood. This panel was designed to facilitate the use of single-cell technologies for high-dimensional analysis of immune cells. This development is expected to contribute to advancements in the study of immune cells.

Thermo Fisher Scientific Inc. acquired PPD, Inc. for $17.4 billion in 2021, a move aimed at expanding its product line and increasing its market share in the pharmaceutical and biotech sectors. This acquisition is expected to provide Thermo Fisher with a competitive edge and enable it to offer a broader range of services to its clients.

Beckman Coulter, Inc. partnered with the National Cancer Institute (NCI) in 2020 to develop and test a new panel of cell surface markers for use in cancer research. The panel includes markers for identifying immune cells that infiltrate tumors, and is intended to support the development of new cancer immunotherapies. This collaboration is expected to pave the way for the development of more effective cancer treatments.

In 2020, F. Hoffmann-La Roche AG acquired Promedior, Inc., a biotechnology company that specializes in the development of innovative medicines for fibrotic disorders. This acquisition was intended to strengthen Roche's position in the biotech sector and bolster its pipeline of cutting-edge treatments. This move is expected to accelerate the development of new therapies for fibrotic disorders, which are a growing health concern worldwide.

Competitive Landscape:

The life sciences and diagnostic tools industry is expanding, with many key players vying for market share. Here are some of the top companies operating in this field:

BD Biosciences is a major player in the life sciences industry, offering a variety of products and services, including cell analysis and research tools. In 2021, the company introduced a new panel of cell surface markers for identifying immune cells in human blood, intended to support high-dimensional study of immune cells.

Beckman Coulter, Inc. partners with organizations to develop and evaluate new panels of cell surface markers for use in cancer research. In 2020, the company collaborated with the National Cancer Institute (NCI) to create a new panel of cell surface markers to help develop fresh cancer immunotherapies.

Thermo Fisher Scientific Inc. purchased PPD, Inc. for $17.4 billion in 2021. The move was intended to bolster Thermo Fisher's product line and expand its market share in the pharmaceutical and biotech sectors.

Bio-Rad Laboratories, Inc. provides products and services for life science research, clinical diagnostics, and biopharmaceutical production. In 2021, the company launched a new digital PCR system to support research in the fields of genomics, cancer research, and infectious disease.

Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates in the pharmaceuticals and diagnostics sectors. In 2020, the company purchased Promedior, Inc. to expand its pipeline of cutting-edge treatments for fibrotic disorders.

QIAGEN N.V. provides sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. In 2020, the company partnered with DiaSorin S.p.A. to create new serology tests to detect antibodies against SARS-CoV-2.

Sony Biotechnology Inc. develops flow cytometry systems for use in research and clinical diagnostics. In 2021, the company launched a new instrument that offers high-throughput cell sorting and analysis capabilities for a wide range of applications.

Abcam plc provides research tools for life science researchers, including antibodies, proteins, and assays. In 2020, the company expanded its product line by acquiring Expedeon AG, a provider of reagents and assays for protein research.

Request a customization of the report @

Cell Signaling Technology, Inc. provides research tools and services for studying the signaling pathways that regulate cell behavior. In 2021, the company launched a new product line of high-quality antibodies for use in a wide range of research applications.

Sigma-Aldrich Co. LLC. provides a range of products and services for research in the life sciences and diagnostics industries. The company's offerings include biochemicals, reagents, and analytical tools.

Browse More Reports:

Hematological Cancers Therapeutics Market- @

Vitamin D Market- @

Cancer Supportive Care Drugs Market- @

Dental Implants Market- @

Neurostimulation Devices Market- @

Nikhil Morankar
Reports and Data
+1 2127101370
email us here
Visit us on social media: